| Current issues regarding treatment of mitochondrial fatty acid oxidation disorders. | |
| | |
MedLine Citation:
|
PMID: 20830526 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Treatment recommendations in mitochondrial fatty acid oxidation (FAO) defects are diverse. With implementation of newborn screening and identification of asymptomatic patients, it is necessary to define whom to treat and how strictly. We here discuss critical questions that are currently under debate. For some asymptomatic long-chain defects, long-chain fat restriction plays a minor role, and a normal diet may be introduced. For patients presenting only with myopathic symptoms, e.g., during exercise, treatment may be adapted to energy demand. As a consequence, patients with exercise-induced myopathy may be able to return to normal activity when provided with medium-chain triglycerides (MCT) prior to exercise. There is no need to limit participation in sports. Progression of retinopathy in disorders of the mitochondrial trifunctional protein complex is closely associated with hydroxyacylcarnitine accumulation. A strict low-fat diet with MCT supplementation is recommended to slow or prevent progression of chorioretinopathy. Additional docosahexanoic acid does not prevent the decline in retinal function but does promote nonspecific improvement in visual acuity and is recommended. There is no evidence that L-carnitine supplementation is beneficial. Thus, supplementation with L-carnitine in a newborn identified by screening with either a medium-chain or long-chain defect is not supported. With respect to the use of the odd-chain medium-chain triglyceride triheptanoin in myopathic phenotypes, randomized trials are needed to establish whether triheptanoin is more effective than even-chain MCT. With increasing pathophysiological knowledge, new treatment options have been identified and are being clinically evaluated. These include the use of bezafibrates in myopathic long-chain defects. |
| | |
Authors:
|
Ute Spiekerkoetter; Jean Bastin; Melanie Gillingham; Andrew Morris; Frits Wijburg; Bridget Wilcken |
Related Documents
:
|
17296516 - Effect of ramadan fasting on fuel oxidation during exercise in trained male rugby players. 21671146 - Predictors of an ischemic electrocardiographic response in patients with exercise-induc... 21157516 - The respiratory exchange ratio is associated with fitness indicators both in trained an... 17486166 - Determination of "fatmax"with 1 h cycling protocols of constant load. 21890226 - Aerobic and resistance training effects compared to aerobic training alone in obese typ... 8493846 - Acetylcholine level in the brain and other organs of the bivalve anodonta cygnea l. and... |
Publication Detail:
|
Type: Journal Article; Review Date: 2010-09-10 |
Journal Detail:
|
Title: Journal of inherited metabolic disease Volume: 33 ISSN: 1573-2665 ISO Abbreviation: J. Inherit. Metab. Dis. Publication Date: 2010 Oct |
Date Detail:
|
Created Date: 2010-09-29 Completed Date: 2011-01-28 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 7910918 Medline TA: J Inherit Metab Dis Country: Netherlands |
Other Details:
|
Languages: eng Pagination: 555-61 Citation Subset: IM |
Affiliation:
|
Department of General Pediatrics, University Children's Hospital, Duesseldorf, Germany. ute.spiekerkoetter@uni-duesseldorf.de |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Energy Metabolism*
/
genetics Evidence-Based Medicine Fatty Acids / metabolism* Genotype Humans Lipid Metabolism, Inborn Errors / complications, diagnosis, enzymology, genetics, therapy* Mitochondria / enzymology* Mitochondrial Diseases / complications, diagnosis, enzymology, genetics, therapy* Oxidation-Reduction Phenotype Practice Guidelines as Topic Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Fatty Acids |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Fatty acid profile in patients with phenylketonuria and its relationship with bone mineral density.
Next Document: Modulating malignant epithelial tumor cell adhesion, migration and mechanics with nanorod surfaces.